Zobrazeno 1 - 10
of 988
pro vyhledávání: '"Tezacaftor"'
Publikováno v:
Italian Journal of Pediatrics, Vol 50, Iss 1, Pp 1-4 (2024)
Abstract Background Elexacaftor-tezacaftor-ivacaftor (ETI) is a transmembrane conductance regulator modulator that significantly improves lung function in patients affected by cystic fibrosis (CF). This triple drug is currently not indicated in liver
Externí odkaz:
https://doaj.org/article/e7cfa1ef8c2b4f4ab006f0f1672bb177
Autor:
Chiara Lanfranchi, Carmela Rizza, Maria Chiara Russo, Irene Borzani, Salvatore Alessio Angileri, Erica Nazzari, Gianfranco Alicandro, Francesco Blasi, Valeria Daccò
Publikováno v:
International Journal of Infectious Diseases, Vol 147, Iss , Pp 107190- (2024)
The introduction of CFTR modulator drugs like elexacaftor-tezacaftor-ivacaftor (ETI) has transformed the management of cystic fibrosis (CF), significantly improving symptoms, lung function, and quality of life, while reducing reliance on intravenous
Externí odkaz:
https://doaj.org/article/16c9140f887340b1aa3f2a8d9ce36f1b
Autor:
Anna-Maria Dittrich, Sarah Sieber, Lutz Naehrlich, Manuel Burkhart, Sylvia Hafkemeyer, Burkhard Tümmler
Publikováno v:
International Journal of Infectious Diseases, Vol 139, Iss , Pp 124-131 (2024)
Objectives: The impressive improvements of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) function by elexacaftor/tezacaftor/ivacaftor (ETI) result in changes in the detection frequencies of Staphylococcus aureus (SA) and Pseudomonas
Externí odkaz:
https://doaj.org/article/9f567487b5bf44928dc16de06e7aa09d
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
JAAD Case Reports, Vol 44, Iss , Pp 68-70 (2024)
Externí odkaz:
https://doaj.org/article/9bc220cc761e4b92a70228408824f597
Autor:
Christian Martin, Douglas V. Guzior, Cely T. Gonzalez, Maxwell Okros, Jenna Mielke, Lienwil Padillo, Gabriel Querido, Marissa Gil, Ryan Thomas, Marc McClelland, Doug Conrad, Stefanie Widder, Robert A. Quinn
Publikováno v:
Respiratory Research, Vol 24, Iss 1, Pp 1-14 (2023)
Abstract Background Cystic fibrosis (CF) is a genetic disorder causing poor mucociliary clearance in the airways and subsequent respiratory infection. The recently approved triple therapy Elexacaftor–Tezacaftor–Ivacaftor (ETI) has significantly i
Externí odkaz:
https://doaj.org/article/3d27b87ba66b4ebd91cc2f4f4795e285
Autor:
Francisco Hevilla, Nuria Porras, María Victoria Girón, María García-Olivares, Marina Padial, Francisco José Sánchez-Torralvo, Casilda Olveira, Gabriel Olveira
Publikováno v:
Nutrients, Vol 16, Iss 19, p 3293 (2024)
Background: The combination of elexacaftor–tezacaftor–ivacaftor modulators (ETI) has improved clinical outcomes for people with cystic fibrosis (pwCF). Objectives: This study aimed to evaluate changes in nutritional and morphofunctional assessmen
Externí odkaz:
https://doaj.org/article/812e4b32fc2747818a4945e8a055b88d
Autor:
Thomas Keens, Veena Hoffman, Ia Topuria, Ken Elder, Shannon Cerf, Kyra Mulder, Jon Roberts, Jerimiah Lysinger, Maria Del Carmen Reyes, Maria Berdella, Anne Marie Cairns, Manu Jain, Vaidyanathan Ganapathy, Yiyue Lou, Bassem Morcos, Chuntao Wu, Laura Sass
Publikováno v:
Heliyon, Vol 10, Iss 7, Pp e28508- (2024)
Background: Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has been shown to be safe and efficacious in people with cystic fibrosis (CF) aged ≥2 years. Here, we describe results from an observational study assessing change in burden of illness foll
Externí odkaz:
https://doaj.org/article/9304463ac983441caa1631b1fb16f40b
Autor:
Mehdia Amini, Kevin Yu, Jessica Liebich, Vaishaliben Ahir, Emily Wood, Stewart Albert, Sandeep Dhindsa
Publikováno v:
Journal of Clinical & Translational Endocrinology, Vol 35, Iss , Pp 100332- (2024)
Objective: Patients with Cystic Fibrosis related diabetes [CFRD] are treated with insulin and high calorie diets to maintain body mass. The combined CFTR modulator elexacaftor/tezacaftor/ivacaftor [ETI] decreases pulmonary exacerbations and improves
Externí odkaz:
https://doaj.org/article/5254dbbba2b749299e73602b23269a06